The Starting Line, Not the Finish Line: Paul Grand on What Makes MedTech Innovator Work
Most promising medtech startups don't fail because the idea was wrong. They fail because of a strategic mistake made years earlier, often on advice from someone who had never brought a medical product to market. Paul Grand saw that pattern again and again as a venture investor, and it's why he started MedTech Innovator.
Paul founded eight companies across tech, biopharma and medtech before spending nearly 12 years in venture capital. MedTech Innovator (MTI) began in 2013 as ten companies pitching on a conference stage. It is now the world's largest healthcare accelerator, with 953 graduates drawn from more than 15,000 applicants. In this episode, the first of our MTI bonus miniseries, he and Lindsey Dinneen talk about how the accelerator selects and supports companies, what he tells founders before they pitch, and what to know before applying.
"Two Years of Meetings in Three Days"
Every MTI applicant is reviewed by an expert panel and gets feedback, even if it never advances. Last cycle, that meant 1,835 applications for 65 accelerator spots. The top 180 to 200 companies move on to the Radar Forum, an invite-only, three-day event where about 250 evaluators meet them in pre-arranged small groups. Clinicians, investors, payers, regulatory and reimbursement experts, and people from FDA and CMS sit at the same table, and every one of them asked to meet that company. One founder's advisor summed it up afterward: they had just had two years of meetings in three days. The results hold up over time. Paul notes that 70 to 90 percent of medtech companies are typically gone at the ten-year mark. Among MTI graduates, about 95 percent are still operating or have been acquired.
Mentorship Is Really Relationship Building
Each company is championed by a sponsor: a strategic like Edwards, J&J or Olympus, or a society like the American Heart Association. Those partners meet with their companies as often as weekly for four to five months. Paul sees it as a chance to intervene early, advising on first indication, trial design and the evidence payers will want, "two years earlier, three years earlier." Edwards' acquisition of Endotronix, he says, traces back to a relationship built at MTI. Founders also get a peer network. MTI groups them into small leadership pods that stay on speed dial long after the program. Paul hears from alumni who prepped for a big meeting by messaging their pod, and from some whose pod members ended up in their wedding party.
Pitch the Problem, Not the Disease
Paul has coached thousands of pitches, and the same fixes keep coming up. Declutter the slides, because "you're either listening or you're reading. You cannot do both." Don't recycle your sit-down investor deck for a stage. Name your product in the first minute and define the specific problem you solve: a diagnostics company isn't solving breast cancer, it's solving detection that hasn't meaningfully changed in more than a century. And tell the room when you're coming to market and what this round of funding actually buys.
FDA Clearance Is the Starting Line
Too many startups fund themselves to FDA clearance as if it were the finish line. Paul argues it's the starting line, with reimbursement, adoption and commercial execution still ahead. FDA has recognized the same gap with its TAP program, which Paul says drew on MTI's model, and MTI is now working with FDA on a playbook for innovators.
Why This Matters
The mistakes Paul describes are rarely about the technology. They come from linear thinking: regulatory first, reimbursement "later," and funding sized to clearance and no further. Structured, early feedback from the people who will eventually buy, pay for and use a product is how teams catch those mistakes while they're still cheap to fix.
For founders who never join a cohort, the lessons still apply. Build a pitch for the room, define the problem precisely, and plan funding to an inflection point beyond clearance. Even working through MTI's application, which Paul says can take a couple of hours, surfaces the gaps investors and strategics will find later.
What to Watch
Applications for MTI's 2027 cohort close December 1, and the 2027 Radar Forum heads to Washington, DC in April. Watch for MTI's playbook with FDA, which aims to bring some of the accelerator's guidance to every innovator. And stay tuned for the rest of this miniseries, where founders from the 2026 cohort share their own stories.
Catch the full episode here: https://www.projectmedtech.com/projectmedtechpodcast/episode/26c7ac00/episode-286-paul-grand-ceo-at-medtech-innovator-a-look-inside-the-worlds-largest-healthcare-accelerator
Helpful Links
Thank you to our sponsors: Ward Law, Wheelhouse DMG, and JumpStart Inc.



Comments